Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial-Reference-Cited by-同舟云学术

Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial

Published:2018-04-30 Issue:9 Volume:20 Page:1290-1299
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Ravassa Susana¹,Trippel Tobias²,Bach Doris²,Bachran Diana²,González Arantxa¹,López Begoña¹,Wachter Rolf³,Hasenfuss Gerd³,Delles Christian⁴,Dominiczak Anna F.⁴,Pieske Burkert²⁵⁶,Díez Javier¹⁷,Edelmann Frank²³⁵

Affiliation:

1. University of Navarra, CIMA, Program of Cardiovascular Diseases, IdiSNA, Navarra Institute for Health Research; Pamplona, Spain, CIBERCV, Carlos III Institute of Health; Madrid Spain

2. Institute for Internal Medicine and Cardiology; Charité Universitätsmedizin Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin; Berlin Germany

3. Department of Cardiology and Pneumology; University of Göttingen Medical Centre Göttingen, Göttingen, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Göttingen; Göttingen Germany

4. Institute of Cardiovascular and Medical Sciences; University of Glasgow; Glasgow UK

5. Berlin Institute of Health (BIH); Berlin Germany

6. Deutsches Herzzentrum Berlin (DHZB), Department of Cardiology; Berlin Germany

7. University of Navarra Clinic; Departments of Cardiology and Cardiac Surgery, and Nephrology; Pamplona Spain

Funder

Seventh Framework Programme

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ejhf.1194/fullpdf